This prospective randomized study compared ciclosporin A ( CsA ) - to-tacrolimus conversion ( group A , target tacrolimus trough level 6-8 ng/ml ) vs CsA minimization ( group B , target CsA trough level 80-100 ng/ml ) with regard to efficacy and safety in patients with CAN and deteriorating allograft function .
